Baiocchi Otavio C G, Colleoni Gisele W B, Navajas Eduardo V, Duarte Luiz Claudio C, Alves Antonio C, Andrade Ana Lucia S S, Kerbauy Jose, Oliveira Jose Salvador R
Hematology and Transfusion Service, Universidade Federal de São Paulo, Brazil.
Acta Oncol. 2002;41(2):192-6. doi: 10.1080/028418602753669599.
Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients were reviewed over a 10-year-period, divided into Group A, including 13 NHL cases treated before the highly active antiretroviral therapy (HAART) era, and Group B, including 7 patients who received HAART. A Kaplan-Meier survival curve was performed and log-rank was applied to assess statistical differences between the groups. In group A, the median CD4 count was 36 cells/mm3. No complete remission was found. In group B, the median CD4 count was 137 cells/mm3. Four patients (57.0%) are still alive and in complete remission. Group A had a median survival of 5 months and group B 31 months (p = 0.0032). Our results are in agreement with recent reports in that a higher CD4 count and better immune status achieved with HAART is predictive of a better outcome. We found that HAART in combination with chemotherapy improves overall survival of NHL patients without increasing adverse effects.
对10年间20例HIV感染患者的系统性非霍奇金淋巴瘤（NHL）病例进行了回顾性研究，分为A组，包括13例在高效抗逆转录病毒治疗（HAART）时代之前接受治疗的NHL病例，以及B组，包括7例接受HAART治疗的患者。绘制了Kaplan-Meier生存曲线，并应用对数秩检验来评估两组之间的统计学差异。A组的CD4细胞计数中位数为36个/立方毫米，未发现完全缓解病例。B组的CD4细胞计数中位数为137个/立方毫米，4例患者（57.0%）仍存活且处于完全缓解状态。A组的中位生存期为5个月，B组为31个月（p = 0.0032）。我们的结果与近期报告一致，即HAART使CD4细胞计数升高且免疫状态改善预示着更好的预后。我们发现HAART联合化疗可提高NHL患者的总生存率，且不增加不良反应。
